Sweden’s Karolinska Development says that Bo Jesper Hansen, chairman of the company's board, has decided not stand for re-election at the 2017 Annual General Meeting. 20 April 2017
French drugmaker Ipsen on Friday announced the appointment of Dr Alexandre Lebeaut as executive vice-president, R&D, and chief scientific officer, effective immediately. 18 April 2017
Privately-held UK biotech firm Destiny Pharma has appointed Neil Clark as chief executive and member of the board of directors, effective immediately. 13 April 2017
In a finding that might add weight to industry calls for continued free movement of vital talent post-Brexit, a study has shown that country managers and European heads in UK pharma are far more internationally diverse than their French and German counterparts. 12 April 2017
David Hung, the founder and former chief executive of Medivation, an oncology-focused biopharma bought by US pharma giant Pfizer for $14 billion last year, has switched his attention to dementia in his role. 11 April 2017
USA-based Marinus Pharmaceuticals, a biotech company focused on developing treatments for epilepsy and neuropsychiatric disorders, has appointed Lorianne Masuoka as chief medical officer. 11 April 2017
Tim Harris has been appointed as executive vice president of R&D at Bioverativ, a new company focussed on hemophilia and other rare blood disorders. 11 April 2017
French pharma major Sanofi (Euronext: SAN) has promoted Bill Sibold to the post of executive vice president Sanofi Genzyme, effective July 1, 2017. In this role, Mr Sibold will be a member of the executive committee. 5 April 2017
Respiratory diseases specialist Verona Pharma has announced the appointment of Richard Hennings to the company’s senior management team as commercial director. 31 March 2017
Takeda Pharmaceuticals says that Ricardo Marek has been appointed as the president of the Emerging Markets Business Unit (EM BU), based in Singapore, effective April 1, 2017 31 March 2017
Takeda Pharmaceutical said today that Giles Platford will assume the role of president of its Europe and Canada (EUCAN) business unit. In this role he will lead business operations in the region effective April 1, 2017. 30 March 2017
Daniel Gallagher – who from November 2011 to October 2015 was Commissioner of the US Securities and Exchange Commission (SEC) – has joined Netherlands-incorporated drugmaker Mylan as the company’s chief legal officer. 28 March 2017
Investors were clearly impressed by the appointment of Paul Bisaro as the chief executive of USA-based generics company Impax Laboratories as the firm’s share value shot up by 37% on Monday to $12.70. 28 March 2017
US biotech firm Alexion Pharmaceuticals has appointed Ludwig Hantson as chief executive and member of the board of directors, effective immediately. 27 March 2017
Claude Bertrand started on Monday in his new role as general director of research and development (R&D) and chief scientific officer (CSO) at privately-held French drugmaker Servier. 27 March 2017
US-based Boston Biomedical is making new senior appointments in oncology, as the company’s founder Chiang J. Li steps down from his role as chief executive. 23 March 2017
The US subsidiary of Japanese pharma major Eisai has appointed Kirk Shepard as senior vice president, global medical affairs of the Oncology Business Group. 17 March 2017
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024